Nova Scotia Provincial Pharmacare Programs Request for Coverage of Ofev (nintedanib)

| PATIENT INFORMATION | | | |
|--|--------------------|-----------------|--------------------|
| PATIENT SURNAME | PATIENT GIVEN NAME | HEALTH CARD NUM | MBER DATE OF BIRTH |
| PATIENT ADDRESS | | | |
| | | | |
| DIAGNOSTIC INFORMATION | | | |
| ☐ Idiopathic pulmonary fibrosis (IPF) | | | |
| Chronic fibrosing interstitial lung disease with a progressive phenotype (progressive fibrosing ILD) | | | |
| INITIAL REQUEST | | | |
| For All Patients – Baseline Information (Prior to Ofev Initiation) | | | |
| | - | • | |
| Patient's baseline % predicted Forced Vital Capacity (FVC): Date on which baseline FVC was obtained: | | | |
| | | | |
| For Patients with Idiopathic Pulmonary Fibrosis (IPF) | | | |
| Diagnosis of IPF has been confirmed by a respirologist and a high-resolution CT scan within the previous 24 months: | | | |
| ☐ YES ☐ NO | | | |
| All other causes of restrictive lung disease (e.g., collagen vascular disorder or hypersensitivity pneumonitis) have been excluded: | | | |
| ☐ YES ☐ NO | | | |
| For Patients with Chronic Fibrosing Interstitial Lung Disease with a Progressive Phenotype (Progressive Fibrosing ILD) | | | |
| Diagnosis of chronic fibrosing ILD with a progressive phenotype has been confirmed by a specialist with experience in the diagnosis and management of ILD: | | | |
| ☐ YES ☐ NO | | | |
| RENEWAL REQUEST | | | |
| For All Patients – Post-Treatment Info | rmation | | |
| Patient's current % predicted Forced Vital Capacity (FVC): | | | |
| Date on which current FVC was obtained: | | | |
| PRESCRIBER NAME & ADDRESS: | | | |
| | | | |
| LICENCE # | PRESCRI | BER SIGNATURE | DATE |

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

Please Return Form To: Nova Scotia Pharmacare Programs

P.O. Box 500, Halifax, NS B3J 2S1

Fax: (902) 496-4440

